RPL17P12

Across TCGA pan-cancer cohorts, RPL17P12 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of RPL17P12’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RPL17P12 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL17P12 is over-expressed in tumor.

STAD are the cancer types where RPL17P12 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL17P12 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Male	IV	+0.114	.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

RPL17P12–STAD

Open the STAD breakdown →